Literature DB >> 32936005

Splenic Primary Solid Tumors : Does a Preoperative Histopathology Diagnosis Really Matter?

Mauricio Gonzalez-Urquijo1,2, Mario Rodarte-Shade1,2, Gerardo Gil-Galindo1,2.   

Abstract

BACKGROUND: The present study aims to present a case series of patients who underwent splenectomy for splenic primary solid tumors without preoperative histopathologic diagnosis.
METHODS: From 2013 to 2019, 12 patients underwent splenectomy for solid primary splenic tumors at 3 different academic medical centers. All electronic medical records were retrospectively reviewed.
RESULTS: Seven (58.3%) patients were women, and 5 (41.6%) were male. The median age was 48 years (range: 25-72 years). In 8 (66.6%) patients, a conventional approach was performed. In 2 (16.6%), a hand-assisted laparoscopic surgery procedure was completed, and in other 2 (16.6%) patients, a laparoscopic approach was auspiciously achieved. Median operative time was 135 minutes (range: 60-210 minutes), and median blood loss was 500 mL (range: 200-1500 mL). Procedure-related morbidity was found in 2 (16.6%) patients, and the mortality rate was 0%. The final histopathologic diagnosis was lymphoma in 5 (41.6%) patients, lymphangioma in 3 (25%) patients, hamartoma in 2 (16.6%) patients, angiosarcoma, and sclerosing angiomatoid nodular transformation (SANT) in 1 (8.3%) case each.
CONCLUSION: Splenectomy should be the treatment of choice when encountering a primary splenic tumor without the need for preoperative fine-needle aspiration biopsy, avoiding the complications this technique entails.

Entities:  

Keywords:  primary splenic tumor; solid splenic tumor; spleen; splenectomy

Mesh:

Year:  2020        PMID: 32936005     DOI: 10.1177/0003134820951480

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  1 in total

1.  Myoid Angioendothelioma: A Rare Benign Splenic Tumor.

Authors:  Vladimir Milosavljevic; Boris Tadic; Mauricio Gonzalez-Urquijo; Djordje Knezevic; Nikola Grubor
Journal:  Balkan Med J       Date:  2021-05       Impact factor: 2.021

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.